Login
800-633-4743
Login
Back to Credit Category
search for
or search by
Order By Rank
Order By Popularity
Order By Posted Date
Order By Title
10 Items Per Page
20 Items Per Page
40 Items Per Page
60 Items Per Page
80 Items Per Page
100 Items Per Page
Results 1 - 20 of 1000
1
2
3
4
5
6
7
8
9
10
>>
Association Between GLP-1 Receptor Agonist Use and Worsening Mental Illness in People With Depression and Anxiety in Sweden: A National Cohort Study.
Posted Date: 6/4/2026 8:39:00 PM
Issue: Psychiatry - May 2026 - Vol. 54 - No. 8
Editorial Advisor: Duy Nguyen, MD
In patients with diabetes and depression, semaglutide may offer psychiatric benefits in addition to metabolic effects, rather than worsening mood or anxiety.
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Posted Date: 6/4/2026 8:39:00 PM
Issue: Psychiatry - May 2026 - Vol. 54 - No. 8
Editorial Advisor: Lauren Chatham, MD
Mebufotenin (GH001) is superior to placebo in efficacy, safety, and tolerability for treatment of patients with treatment-resistant depression.
Methylphenidate Treatment and Risk of Psychotic Disorder.
Posted Date: 6/4/2026 8:39:00 PM
Issue: Psychiatry - May 2026 - Vol. 54 - No. 8
Editorial Advisor: Lauren Chatham, MD
Methylphenidate treatment is not associated with a significantly increased risk of psychotic disorders.
Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta-Analysis.
Posted Date: 6/2/2026 2:20:00 PM
Issue: Gastroenterology - May 2026 - Vol. 45 - No. 1
Editorial Advisor: Ronald L. Koretz, MD
According to this systematic review, use of statins improves survival in patients with cirrhosis.
A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients With Supraventricular Arrhythmia (Landi-UP).
Posted Date: 5/28/2026 1:59:00 PM
Issue: Cardiology - May 2026 - Vol. 53 - No. 12
Editorial Advisor: Thomas Metkus, MD
Asundexian for Secondary Stroke Prevention.
Posted Date: 5/28/2026 1:59:00 PM
Issue: Cardiology - May 2026 - Vol. 53 - No. 12
Editorial Advisor: George J. Linsenmeyer III, MD, FACC, FSCAI
Factor XIa inhibition is an emerging treatment paradigm in various cardiovascular diseases without an increase in bleeding.
Bleeding Risk With Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Posted Date: 5/28/2026 1:59:00 PM
Issue: Cardiology - May 2026 - Vol. 53 - No. 12
Editorial Advisor: George J. Linsenmeyer III, MD, FACC, FSCAI
In patients with acute venous thromboembolism, the risk of less major and less clinically relevant bleeding is significantly lower with apixaban compared to rivaroxaban.
Discontinuation of Beta-Blocker Therapy After Myocardial Infarction.
Posted Date: 5/28/2026 1:59:00 PM
Issue: Cardiology - May 2026 - Vol. 53 - No. 12
Editorial Advisor: George J. Linsenmeyer III, MD, FACC, FSCAI
A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients With Supraventricular Arrhythmia (Landi-UP).
Posted Date: 5/23/2026 12:47:00 AM
Issue: Critical Care Medicine - May 2026 - Vol. 33 - No. 10
Editorial Advisor: Thomas Metkus, MD
Association Between Initial Norepinephrine Dose and Minute by Minute Mean Arterial Pressure.
Posted Date: 5/23/2026 12:47:00 AM
Issue: Critical Care Medicine - May 2026 - Vol. 33 - No. 10
Editorial Advisor: Frank D. Brodkey, MD, FCCM
Vasopressin Initiation Timing and In-Hospital Mortality in Septic Shock: An Observational Study of Large Public Databases.
Posted Date: 5/21/2026 7:48:00 PM
Issue: Hospital Medicine - May 2026 - Vol. 24 - No. 11
Editorial Advisor: Frank D. Brodkey, MD, FCCM
Oral Adverse Events Associated With Anti-Tumor Necrosis Factor-Alpha Therapies: Using a Large Real-World Dataset.
Posted Date: 5/20/2026 1:47:00 PM
Issue: Oral & Maxillofacial Surgery - May 2026 - Vol. 44 - No. 8
Editorial Advisor: Jeffrey D. Bennett, DMD
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial.
Posted Date: 5/19/2026 5:18:00 PM
Issue: Neurology - May 2026 - Vol. 33 - No. 6
Editorial Advisor: Craig M. Garver, MD
In this phase 3 TEMPO I trial, tavapadon safely improved motor function and motor aspects of daily living.
Atropine or Cyclopentolate to Diagnose Premyopia in Preschool Children.
Posted Date: 5/15/2026 7:42:00 PM
Issue: Ophthalmology - May 2026 - Vol. 47 - No. 10
Editorial Advisor: Scott D. Smith, MD, MPH
In young children with a high accommodative amplitude, atropine provides stronger cycloplegia than does cyclopentolate for accurate measurement of refractive error.
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results From the Randomized Phase 3 PULSAR Trial.
Posted Date: 5/15/2026 7:42:00 PM
Issue: Ophthalmology - May 2026 - Vol. 47 - No. 10
Editorial Advisor: Scott D. Smith, MD, MPH
Increasing the dose of aflibercept injection permits longer treatment intervals while maintaining control of neovascularization in patients with exudative age-related macular degeneration.
Systemic Toxicity With Use of Apraclonidine Ophthalmic Drops in Pediatric Patients.
Posted Date: 5/15/2026 7:42:00 PM
Issue: Ophthalmology - May 2026 - Vol. 47 - No. 10
Editorial Advisor: Scott D. Smith, MD, MPH
Central absorption of topical α-2 agonist medications apraclonidine and brimonidine used for treating glaucoma can cause somnolence and cardiorespiratory failure in young children.
Dalbavancin for Treatment of
Staphylococcus aureus
Bacteremia: The DOTS Randomized Clinical Trial.
Posted Date: 5/15/2026 2:39:00 PM
Issue: Family Medicine - May 2026 - Vol. 56 - No. 2
Editorial Advisor: Jay Manoj Brahmbhatt, MD
Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough.
Posted Date: 5/15/2026 2:39:00 PM
Issue: Family Medicine - May 2026 - Vol. 56 - No. 2
Editorial Advisor: Janet L. Barrall, MD
While chronic cough is often associated with gastroesophageal reflux disease, a microaspiration subtype exists that does not respond to proton pump inhibitors.
Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.
Posted Date: 5/15/2026 2:39:00 PM
Issue: Family Medicine - May 2026 - Vol. 56 - No. 2
Editorial Advisor: John Van Loon Sheffield, MD, FACP
Glucagon-like peptide-1 receptor agonists are associated with an increased risk of cholelithiasis and gastroesophageal reflux disease, but not other serious gastrointestinal or biliary risk events.
Trimethoprim-Sulfamethoxazole and Acute Respiratory Failure in Adolescents and Young Adults.
Posted Date: 5/15/2026 2:39:00 PM
Issue: Family Medicine - May 2026 - Vol. 56 - No. 2
Editorial Advisor: Douglas S. Paauw, MD, MACP
The 30-day risk of hospital visit with acute respiratory failure has been seen to be higher in those receiving trimethoprim-sulfamethoxazole compared with those receiving amoxicillin or cephalosporins.
1
2
3
4
5
6
7
8
9
10
>>